Aquaculture Vaccines Market Size, Share, Trend, Forecast Report 2026 to 2035
What is Aquaculture Vaccines Market Size?
The Aquaculture Vaccines Market Size is valued at USD 230.05 Million in 2025 and is predicted to reach 455.71 Million by the year 2035 at a 7.2% CAGR during the forecast period for 2026 to 2035.
Aquaculture Vaccines Market Size, Share & Trends Analysis Report By Vaccine Type (Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine, Others), By Route of Administration, By Species, By Application, By Region, And By Segment Forecasts, 2026 to 2035.
Aquaculture Vaccines Market Key Takeaways:
|
Vaccination creates or enhances immunity against a particular illness or group of illnesses. There is always a possibility of pathogenic outbreaks in aquaculture methods, impacting the farm's output. Vaccines for aquaculture are used to shield the fish from any infection. Increased demand for food products made from aquatic animals, such as oil, protein powders, caviar, and meat, as well as the rate of disease progression in marine animals, would restrain the growth of the aquaculture vaccines market. Over the forecast period, there is expected to be a rise in demand for commercial aquaculture vaccines due to the increased prevalence of bacterial diseases among aquatic species. The aquaculture vaccine market has also expanded due to rising global demand for and production of aquatic species.
However, the aquaculture vaccinations business has suffered due to the COVID-19 epidemic. Additionally, it's anticipated that short-term market weakness would result from growing knowledge of the risks associated with animal-to-human virus transmission. Moreover, complicated vaccine production processes, high vaccination costs, and strict regulatory requirements for aquaculture vaccine approval would restrain the market's expansion.
Market Segmentation:
The Aquaculture Vaccines market is segmented on the vaccine type, application, route of administration and species. Based on the vaccine type, the market is segmented into Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine and Others. Based on application, the Aquaculture Vaccines are segmented into Bacterial Infection, Viral Infections, Combined Bacterial and Viral Infections and Others. Based on route of administration, the market is segmented into Immersion Vaccines, Injection Vaccines and Oral Vaccines. Based on species, the market is segmented into Salmon, Seabass and Seabream, Tilapia, Trout, Turbo and Carp.
Based on the vaccine type, the inactivated vaccines segment is accounted as a major contributor to the Aquaculture Vaccines market
Inactivated vaccines dominated the market for vaccinations used in aquaculture. Large quantities of the disease-causing microorganisms are fermented to create inactivated bacterial and viral vaccines. Then, inactivating chemicals like formalin are used to eliminate all the germs. These inactivated organisms have their basic structure, original antigen properties, and form, which causes an immune response. The recombinant vaccines market is projected to expand significantly. Recombinant vaccines can imitate naturally occurring illnesses and induce a potent immune response in inoculated fish. Recombinant vaccines are also simpler to manufacture on a large-scale, commercial basis.
The injection vaccines segment witnessed growth at a rapid rate
Injection vaccines dominated the market share for aquaculture vaccines. Injection vaccinations allow for the direct induction of a systemic immune response by delivering antigens directly into a bodily cavity or muscle. Injection vaccines' superior capacity to cure various bacterial and viral infectious diseases compared to other routes of administration is thus expected to boost industry statistics.
The European Aquaculture Vaccines market holds a significant revenue share in the region
The European Aquaculture Vaccines market is expected to register the highest market share in revenue in the near future. The main drivers propelling this regional market include Norway's position as the region's largest salmon exporter, supportive government and business sector initiatives, growing public concern about the prevalence of antibiotic resistance, and the existence of significant companies. The Norwegian Medicines Agency has specific guidelines and recommendations for autogenous vaccination applications. Additionally, autogenous vaccinations should only be used when commercial vaccines are either not accessible or do not provide adequate protection. In addition, Asia Pacific is projected to expand in the global Aquaculture Vaccines market because of growing demand, a thriving aquaculture industry, encouraging government initiatives, adequate water resources in many regions, and a drive toward sustainable aquaculture, among other factors. Several aquatic species, including tilapia, are abundant in this area.
Competitive Landscape:
Some Major Key Players In The Aquaculture Vaccines Market:
- Pharmaq AS (Zoetis, LLC) (Norway)
- Merck Animal Health (Merck & Co., Inc.) (USA)
- KoVax Ltd. (Part of Phibro Animal Health) (Israel)
- Hipra (Spain)
- Tecnovax SA (Argentina)
- Veterquimica S.A. (Chile)
- Nisseiken Co. Ltd. (Japan)
- Virbac S.A. (France)
- Elanco (USA)Kyoritsuseiyaku Corporation (Japan)
Aquaculture Vaccines Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2025 | USD 230.05 Million |
| Revenue forecast in 2035 | USD 455.71 Million |
| Growth rate CAGR | CAGR of 7.2% from 2026 to 2035 |
| Quantitative units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | Vaccine type, Route of Administration, Species, Application |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Pharmaq AS (Zoetis, LLC) (Norway), Merck Animal Health (Merck & Co., Inc.) (USA), KoVax Ltd. (Part of Phibro Animal Health) (Israel), Hipra (Spain), Tecnovax SA (Argentina), Veterquimica S.A. (Chile), Nisseiken Co. Ltd. (Japan), Virbac S.A. (France), Elanco (USA) and Kyoritsuseiyaku Corporation (Japan). |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Aquaculture Vaccines Market Segmentation:
By Vaccine Type-
- Inactivated Vaccine
- Attenuated Live Vaccine
- DNA Vaccine
- Others
By Application-
- Bacterial Infection
- Viral Infections,
- Combined Bacterial and Viral Infections
- Others
By Route of Administration-
- Immersion Vaccines
- Injection Vaccines
- Oral Vaccines
By Species-
- Salmon
- Seabass and Seabream
- Tilapia
- Trout
- Turbot
- Carp
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Aquaculture Vaccines Market Size is valued at USD 230.05 Million in 2025 and is predicted to reach 455.71 Million by the year 2035.
Aquaculture Vaccines Market expected to grow at 7.2% CAGR during the forecast period for 2026-2035
Pharmaq AS (Zoetis, LLC) (Norway), Merck Animal Health (Merck & Co., Inc.) (USA), KoVax Ltd. (Part of Phibro Animal Health) (Israel), Hipra (Spain), T
Aquaculture Vaccines market is segmented on the vaccine type, application, route of administration and species, Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine and Others.
The North American region is leading the Aquaculture Vaccines market.